

Seth D. Judson MD<sup>1</sup> and Vincent J. Munster PhD<sup>2</sup> <sup>1</sup>University of Washington, Seattle, WA; <sup>2</sup>National Institute of Allergy and Infection Disease, Hamilton, MT sethj802@uw.edu; www.sethjudson.com





#### Introduction

Early on during the pandemic of coronavirus disease 2019 (COVID-19), many questions arose regarding risks for hospital-acquired or nosocomial transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).<sup>1</sup> Aerosol generating medical procedures (AGMPs), techniques that can generate infectious, virus-laden aerosols, could potentially amplify transmission among healthcare workers (HCWs).<sup>2</sup> Thus, it was widely recommended that HCWs use airborne precautions when performing AGMPs. However, in clinical settings it is often unclear what procedures constitute AGMPs and how the risk varies by procedure or pathogen. We set out to further define AGMPs and assess the risk for nosocomial transmission of SARS-CoV-2 and other high-risk viruses via AGMPs.<sup>3</sup>

## Methods

We identified potential AGMPs and emerging viruses that were high-risk for nosocomial transmission through reviewing experimental and clinical data. Potential AGMPs were those associated with previous virus transmission or mechanically capable of transmission. High-risk viruses were defined as those that cause severe disease in humans for which limited therapies or interventions exist, are infectious via aerosols in humans or non-human primates (NHPs), found in the respiratory tract of infected humans or NHPs, and had previous evidence of nosocomial transmission.<sup>3</sup>

### Conclusions

- 1. Viruses from eight families are high-risk for nosocomial transmission via aerosol-generating medical procedures. All of these viruses are emerging zoonotic RNA viruses.
- 2. There are many potential aerosol-generating medical procedures, which can be divided into those that induce a patient to form aerosols and those that generate aerosols.
- 3. Aerosol-generating medical procedures pose a risk for SARS-CoV-2 transmission given similar aerosol stability to SARS-CoV-1 and increased risk of SARS-CoV-1 transmission with procedures such as intubation.



# **Aerosol-Generating Medical Procedures: Transmission of SARS-CoV-2 and Emerging Viruses**





<u>Kesults</u>								
Induced aerosol generation in M respiratory tract		echanical aerosol generation in respiratory tract			Aerosol Generating Procedure	How/Where Aerosols May Be Generated		
					Bronchoscopy *	Induced cough, respiratory tract		
					Cardiopulmonary resuscitation *	Induced cough, respiratory tract		
					Noninvasive ventilation * (BiPAP, CPAP, HFOV, Trach collar)	Possible mechanical dispersal of aerosols, respiratory tract		
					Tracheal intubation *	Induced cough, respiratory tract		
					Manual ventilation *	Possible mechanical dispersal of aerosols, respiratory tract		
						Surgery (tracheostomy)	Cutting bone and tendon, and irrigation aerosolize blood	
Examples: Intubation, Bronchoscopy, CPR		•	ilation, Suctioning		Sputum induction	Induced cough, respiratory tract		
Virus MERS-CoV	Detection in Upper Respiratory Tract	Detection in Lower Respiratory Tract	Infection via Aerosols	Evidence of Transmission Nosocomial transmission		Nebulizer treatment	Possible mechanical dispersal of aerosols, respiratory tract	
SARS-CoV-1				Likely association with AGMPs		Airway Suctioning	Possible mechanical dispersal of aerosols,	
SARS-CoV-2				Likely association with AGMPs		Laser plume	respiratory tract Mechanical dispersal of	
Junin virus	R		X			Chest physiotherapy	aerosols Induced cough, respiratory	
Lassa virus	<b>M</b>			Nosocomial transmission		Nasogastric tube insertion	tract Induced cough, respiratory	
Machupo virus			R	Nosocomial transmission		Endoscopy procedures	tract	
Crimean-Congo hemorrhagic fever virus	R		лs Ì	Possible association with AGMPs		(ERCP, Transesophageal Echocardiogram)	Induced cough, respiratory tract	
Hantaviruses			Â.	Nosocomial transmission	k	* Possible association with SARS-CoV-1 transmission		
Rift valley fever virus	X					<u>References</u>		
Ebolaviruses			R	Possible association with AGMPs	-	<ol> <li>Judson, S., &amp; Munster, V. (2020). A Framework for Nosocomial Transmission of Emerging</li> </ol>		
Marburg virus	X		X			<ul> <li>Coronaviruses. Infection Control &amp; Hospital Epidemiology, 1-8. doi:10.1017/ice.2020.296</li> <li>2. Judson, S. D., van Doremalen, N., Munster, V. J. (2020). Stability and Viability of SARS-CoV-2. <i>The</i> <i>New England Journal of Medicine</i>. http://doi.org/10.1056/NEJMc2007942</li> <li>3. Judson, S.D.; Munster, V.J. (2019). Nosocomial</li> </ul>		
Influenza A virus (H5N1, H7N9, H1N1)			<b>İ</b>	Nosocomial transmission				
Hendra virus			X	Nosocomial transmission				
Nipah virus			X	Nosocomial transmission	3			
M O	Virus isolated or viral RNA/antigen in human samples. Humans infected via aerosols in laboratory or health settings Generating Medical Procedures. Viruses. 11(10), 9							
Virus isolated or viral RNA found in experimentally infected nonhuman primates (NHPs). NHPs infected via aerosols https://doi.org/10.3390/v11100940								

